At the same time, CD8+T-cells specific to several neoantigens constituted an average of 7.3% of thecirculating pool of CD8+ T-cells and were also detected in tumorfoci, comprising up to 7.2% of the total number of tumor-infiltrating T-cells.No statistically significant results about a correlation between the clinicaleffect and immune response were obtained due to the limited volume andheterogeneity of the samples for each tumor type. The gene discussed is CD8A; the disease is neoplasm.